中国普通外科杂志2025，Vol.34Issue(3)：428-438,11.DOI:10.7659/j.issn.1005-6947.240510
联合放疗的胰腺癌新辅助/转化治疗进展
Progress in neoadjuvant/conversion therapy combined with radiotherapy for pancreatic cancer
摘要
Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis,and surgical resection remains the only potentially curative treatment.However,since most patients are diagnosed at a locally advanced or metastatic stage,the feasibility of upfront surgery is limited.In recent years,neoadjuvant and conversion therapy have emerged as crucial strategies for borderline resectable and locally advanced pancreatic cancer,aiming to increase the R0 resection rate and improve survival outcomes.Studies have shown that FOLFIRINOX and gemcitabine plus nab-paclitaxel are commonly used neoadjuvant chemotherapy regimens,with the former being more suitable for patients with good performance status,while the latter is better tolerated across a broader patient population due to its lower toxicity.Additionally,radiotherapy,such as stereotactic body radiotherapy(SBRT),can enhance local tumor control,increase tumor cell eradication,and minimize damage to normal tissues,thereby optimizing overall treatment efficacy.Despite the significant advantages of this approach,challenges remain,including the management of toxic side effects and the optimization of treatment protocols.Future research will focus on personalized precision medicine,integrating genomic sequencing and radiomics to refine neoadjuvant/conversion therapy strategies and exploring the combination of chemotherapy,radiotherapy,immunotherapy,and targeted therapy to improve long-term survival in pancreatic cancer patients.This paper summarizes recent advancements in neoadjuvant/conversion therapy combined with radiotherapy for pancreatic cancer and discusses its potential role in modulating tumor biology and optimizing treatment strategies.关键词
胰腺肿瘤/肿瘤辅助疗法/转化治疗/放射外科手术Key words
Pancreatic Neoplasms/Neoadjuvant Therapy/Conversion Therapy/Radiosurgery分类
医药卫生引用本文复制引用
许誉诚,仇毓东..联合放疗的胰腺癌新辅助/转化治疗进展[J].中国普通外科杂志,2025,34(3):428-438,11.基金项目
科技部重点研发计划基金资助项目(2020YFA0713800) （2020YFA0713800）
江苏省卫健委重点基金资助项目(ZD2021017). （ZD2021017）
